Tenaya Therapeutics, Inc. TNYA
Set alert
At close · Nov 2
After hours · Nov 2, 7:44 PM ET
- YTD
- -49.30%
- 1 year
- -74.93%
- Open
- 0.3716
- Prev close
- 0.3674
- Mkt cap
- 82.28M
- Vol
- 2.29M
- Avg vol
- 2.78M
- EPS
- -0.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.361
- High
- 0.3811
- Forward P/E
- -1.28
- Beta
- 2.35
- Short ratio
- 2.31
- Inst. own
- 73.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.40
- 200-d avg
- 3.26
- 1y target
- 18.50
News
1 week ago defenseworld.net
Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey
Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
1 month ago seekingalpha.com
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
-
1 month ago benzinga.com
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory…
1 month ago globenewswire.com
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden
2 months ago globenewswire.com
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
2 months ago marketbeat.com
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief…
2 months ago seekingalpha.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
-
2 months ago benzinga.com
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of…
2 months ago globenewswire.com
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates…
3 months ago globenewswire.com
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
3 months ago globenewswire.com
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
-
4 months ago benzinga.com
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
4 months ago globenewswire.com
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
5 months ago seekingalpha.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
5 months ago seekingalpha.com
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
-
5 months ago benzinga.com
Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom…
5 months ago globenewswire.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater…
-
5 months ago benzinga.com
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
5 months ago globenewswire.com
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
5 months ago globenewswire.com
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
5 months ago seekingalpha.com
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
5 months ago benzinga.com
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PKP2-related ARVC patients.
5 months ago globenewswire.com
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies…
6 months ago zacks.com
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.24 per share a year ago.
-
6 months ago benzinga.com
Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 62.5 percent increase over losses of…
6 months ago globenewswire.com
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2…
-
6 months ago benzinga.com
Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCTAdditional Presentations at ASGCT Showcase Tenaya's Work with…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
7 months ago benzinga.com
Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of…
-
7 months ago benzinga.com
Tenaya Therapeutics Presents Prelinical Data Of TN-301 At Muscular Dystrophy Association's Clinical & Scientific Conference 2026
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
8 months ago benzinga.com
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
-
9 months ago benzinga.com
Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to…
10 months ago benzinga.com
Tenaya Stock Plunges After $60 Million Equity Offering
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
10 months ago benzinga.com
S&P 500 Down 1%; Broadcom Earnings Top Views
S&P 500 Down 1%; Broadcom Earnings Top Views
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
10 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $5 to $3.
10 months ago benzinga.com
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings
-
10 months ago benzinga.com
Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.
-
10 months ago benzinga.com
Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
10 months ago benzinga.com
Tenaya Therapeutics Reports Interim RIDGE‑1 Trial Data For TN‑401 Gene Therapy In PKP2‑Mutated ARVC
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden…
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
-
11 months ago benzinga.com
Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 60 percent increase over losses of…
-
11 months ago benzinga.com
Reported Saturday, Tenaya Therapeutics Reports TN-201 Well Tolerated At 3E13 And 6E13 vg/kg With Managed Immunogenicity And No Dose-Limiting Toxicities In MyPEAK-1
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular ResearchTN-201 Has Been Generally Well Tolerated at Both…
-
12 months ago benzinga.com
FDA Places Clinical Hold On Tenaya Therapeutics' TN-201 Trial, Requests Protocol Amendment For Patient Monitoring And Immunosuppression Management
The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenaya Therapeutics, Inc.'s ("Tenaya") Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated…
-
12 months ago benzinga.com
Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…